Jazz Pharma's decision to revoke U.S. patent for rival narcolepsy drug

Published Date: 02 Mar 2023

A U.S. court on Friday ordered Jazz Pharmaceuticals to revoke its patents related to its flagship narcolepsy drug Xyrem from the FDA-approved brand name drug after winning a case against Avadel foe CNS Pharmaceuticals.

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Personalized Breast Cancer Treatment; Insights Into HPV in Men; Exercise and Cancer

2.

Advanced Solid Tumors May Benefit from Investigative Immunotherapy Combo.

3.

Even after a partial ban, asbestos is still used and is a deadly carcinogen, according to the EPA.

4.

Making informed decisions and managing regret after prostate cancer treatment

5.

Scientists identify dual protein targets to weaken pancreatic cancer defenses


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot